Otitis Media

conjunctivitis is caused by :: Article Creator What Is Conjunctivitis (Pink Eye)? Symptoms, Diagnosis And Treatment There are four main types of conjunctivitis: viral, allergic, bacterial and chemical. However, there are other, less common types such as immune-mediated and contact lens-related conjunctivitis. Viral Conjunctivitis Viral conjunctivitis is the most common form of pink eye, accounting for around 80% of cases . It's caused by a virus, such as the common cold. It may affect both eyes and can be spread through contact with an infected person's discharge, coughing or sneezing. "Any virus that causes a cold or respiratory flu can also land in the eye and cause pink eye," explains Arthur Lavin, M.D., FAAP, a pediatrician at Akron Children's Hospital in Beachwood, Ohio. According to Dr. Lavin, some of the most common viruses causing viral conjunctivitis include: Adenovirus (a virus that typically causes colds)

absolute glaucoma :: Article Creator Are You Suffering From The 'silent Thief Of Sight'? Five Warning Signs Of Vision-robbing Condition Glaucoma Revealed - And The Celebrities Living With It By Chloe Louise Updated: 08:42 EDT, 23 March 2023 Eye pain, blurred vision and vomiting are all tell-tale signs of an incurable condition known as the 'silent thief of sight'.  However, the symptoms of glaucoma, which affects two per cent of over-40s in the UK, can vary considerably.  They can range from cloudy vision and teary eyes to vomiting. Glaucoma, which develops slowly over many years in most cases, can lead to a loss of vision if not treated promptly. Here, MailOnline reveals five of the lesser-known signs of the condition — and some of the celebrities living with it.  Caryn Johnson, also known professionally as Whoopie Goldberg, first revealed her diagnosis in 2014 The condition is usually caused by fluid slowly building up in t

Specialty

Summary Background The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals with COVID-19. Methods This randomised, placebo-controlled, double-blind, phase 2 trial (AGILE CST-2) was done at five National Institute for Health and Care Research sites in the UK. Eligible participants were adult (aged ≥18 years) outpatients with PCR-confirmed, mild-to-moderate SARS-CoV-2 infection who were within 5 days of symptom onset. Using permuted blocks (block size 2 or 4) and stratifying by site, participants were randomly assigned (1:1) to receive either molnupiravir (orally; 800 mg twice daily for 5 days) plus standard of care or matching placebo plus standard of care. The primary outcome was the time from randomisation to SARS-CoV-2 PCR negativity on nasopharyngeal swabs and was analysed by use of a Bayes